These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 19943762

  • 1. Currently approved prophylactic HPV vaccines.
    Harper DM.
    Expert Rev Vaccines; 2009 Dec; 8(12):1663-79. PubMed ID: 19943762
    [Abstract] [Full Text] [Related]

  • 2. [Diseases caused by human papilloma viruses].
    Zollner U, Schwarz TF.
    Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE, Vuocolo S.
    Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
    [Abstract] [Full Text] [Related]

  • 5. Current prophylactic HPV vaccines and gynecologic premalignancies.
    Harper DM.
    Curr Opin Obstet Gynecol; 2009 Dec; 21(6):457-64. PubMed ID: 19923989
    [Abstract] [Full Text] [Related]

  • 6. Using the new HPV vaccines in clinical practice.
    Widdice LE, Kahn JA.
    Cleve Clin J Med; 2006 Oct; 73(10):929-35. PubMed ID: 17044318
    [Abstract] [Full Text] [Related]

  • 7. HPV vaccination--more answers, more questions.
    Sawaya GF, Smith-McCune K.
    N Engl J Med; 2007 May 10; 356(19):1991-3. PubMed ID: 17494933
    [No Abstract] [Full Text] [Related]

  • 8. [The first vaccine for prevention of cervix cancer and other human papillomavirus related diseases gets a positive evaluation by the European Drug Authority].
    Kinderkrankenschwester; 2006 Sep 10; 25(9):389-90. PubMed ID: 17017592
    [No Abstract] [Full Text] [Related]

  • 9. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.
    Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh Gv, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E.
    Br J Cancer; 2006 Dec 04; 95(11):1459-66. PubMed ID: 17117182
    [Abstract] [Full Text] [Related]

  • 10. The HPV vaccines--which to prefer?
    Bornstein J.
    Obstet Gynecol Surv; 2009 May 04; 64(5):345-50. PubMed ID: 19386141
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
    McCormack PL.
    Drugs; 2014 Jul 04; 74(11):1253-83. PubMed ID: 25022951
    [Abstract] [Full Text] [Related]

  • 13. HPV vaccines - A review of the first decade.
    Harper DM, DeMars LR.
    Gynecol Oncol; 2017 Jul 04; 146(1):196-204. PubMed ID: 28442134
    [Abstract] [Full Text] [Related]

  • 14. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL, Joura EA.
    BioDrugs; 2011 Oct 01; 25(5):339-43. PubMed ID: 21942919
    [Abstract] [Full Text] [Related]

  • 15. Human papillomavirus and vaccination in cervical cancer.
    Wang KL.
    Taiwan J Obstet Gynecol; 2007 Dec 01; 46(4):352-62. PubMed ID: 18182340
    [Abstract] [Full Text] [Related]

  • 16. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
    Prescrire Int; 2008 Jun 01; 17(95):103-4. PubMed ID: 18623911
    [Abstract] [Full Text] [Related]

  • 17. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):325-39. PubMed ID: 20139221
    [Abstract] [Full Text] [Related]

  • 18. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
    Stanley M.
    Gynecol Oncol; 2007 Nov 03; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
    [Abstract] [Full Text] [Related]

  • 19. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    FUTURE I/II Study GroupDepatment of Laboratory Medicine, Lund University, Malmö, Sweden. joakim.dillner@med.lu.se, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.
    BMJ; 2010 Jul 20; 341():c3493. PubMed ID: 20647284
    [Abstract] [Full Text] [Related]

  • 20. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.
    J Natl Cancer Inst; 2012 Nov 21; 104(22):1712-23. PubMed ID: 23104323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.